Summary: Myricetin is a flavonoid that has recently been suggested to interfere with the intestinal folate transport system. The present study was conducted to examine that possibility, focusing on its inhibitory effect on proton-coupled folate transporter (PCFT) as the molecular entity of the transport system. The uptake transport of folate was first examined in the Caco-2 cell as an intestinal epithelial cell model, and its carrier-mediated component, of which the Michaelis constant (K m ) was 0.407 µM, was found to be noncompetitively inhibited by myricetin with an inhibition constant (K i ) of 61 µM. Consistent with that, folate transport by human PCFT stably expressed in Madin-Darby canine kidney II (MDCKII) cells, of which the K m was 1.246 µM, was also noncompetitively inhibited by myricetin with a K i of 130 µM. Thus, myricetin was suggested to inhibit intestinal folate transport by acting noncompetitively on PCFT, although the K m and K i were similarly shifted to some extent to be smaller in Caco-2 cells. Finally, epigallocatechin-3-gallate was also suggested to act in a noncompetitive manner as an inhibitory flavonoid. Care may need to be taken, therefore, in the ingestion of myricetin and some flavonoids to maintain the absorption of folate and antifolate drugs.
Introduction
Malfunction of the intestinal folate transport system, which might be induced by ethanol or its metabolites, has been suspected to be a possible mechanism that could be involved in the malabsorption of folate and, as a consequence, in the increased risk of folate deficiency brought about by continuous ingestion of alcoholic beverages. [1] [2] [3] However, it remains inconclusive and it has recently been suggested that flavonoids, rather than ethanol, might be alternatively involved in that process. 4, 5) As a matter of fact, various dietary and supplemental plant components, including flavonoids, have been of increasing concern for their effects on enzymes and transporters involved in the disposition of drugs and nutrients, although they have also been of interest for their potentially beneficial effects as nutritional and supplemental materials. [6] [7] [8] For example, various flavonoids, typically some of those contained in grapefruit, have been known to inhibit cytochrome P450 (CYP) 3A4 as a metabolizing enzyme, P-glycoprotein (P-gp) as a secretory transporter and organic anion transporting polypeptide 2B1 (OATP2B1) as an uptake transporter. Such effects of flavonoids can be most evident in the small intestine, particularly after the oral ingestion of beverages that contain them concentrated, because this organ is exposed to such flavonoids at high concentrations. Inhibition of CYP3A4 and P-gp, which are involved in drug elimination, in this organ could lead to increased absorption of orally administered substrate drugs and consequently their intensified pharmacological effects. Inhibition of OATP2B1, which has recently been suggested to be involved in drug absorption, in this organ could oppositely lead to decreased absorption of substrate drugs and consequently their weakened pharmacological effects. Such unintended modulations of drug disposition and pharmacological effects could potentially be harmful. Inhibition of nutrient transporters could similarly occur in the small intestine and it could have an impact on the absorption of nutrients and nutritional status. Myricetin, a flavonoid contained abundantly in wines as a component originating from grapes, is one of those that have recently been suggested to interfere with the intestinal folate transport system in the Caco-2 cell as an intestinal epithelial cell model. 4, 5) The present study was conducted to examine that possibility in more detail, focusing on its inhibitory effect on proton-coupled folate transporter (PCFT/SLC46A1) as the molecular entity of the transport system. [9] [10] [11] [12] [13] Although myricetin could act on the transporter in a complicated manner, causing a sustained effect after pretreatment as well as an instantaneous effect by acute exposure, 4) we here particularly focused on the latter. Elucidating mechanisms involved in the functional modulation of PCFT would help in devising strategies to treat or prevent the malabsorption and deficiency of folate and also to optimize the use of antifolate drugs, which are also transported by the same transporter. D-glucose) supplemented with 10 mM MES (pH 5.5), and then uptake assays were started by replacing the substrate-free buffer with one containing [ 3 H]folate as a substrate (0.25 mL). Flavonoids were added only to the uptake buffer containing the substrate to test their inhibitory effects when they were present only during uptake. All the procedures were conducted at 37°C. Assays were stopped by addition of ice-cold substrate-free uptake buffer (2 mL), and the cells were washed two times with 2 mL of the same buffer. The cells were solubilized in 0.5 mL of 0.2 M NaOH solution containing 0.5% SDS at room temperature for 1 h, and the associated radioactivity was determined by liquid scintillation counting, using 3 mL of Clear-sol I (Nacalai Tesque, Kyoto, Japan) as a scintillation fluid, for the evaluation of uptake. Cellular protein content was determined by the method of Lowry et al., using bovine serum albumin as the standard. 14) Similarly, MDCKII cells stably expressing the green fluorescent protein (GFP)-tagged PCFT of human origin, which were prepared as described previously, 10) were grown for 2 days to confluence and uptake assays were conducted using [ 3 H]folate and [ 3 H]methotrexate as substrates. Uptake assays were also conducted in mock cells, which were transfected with empty vector, to estimate nonspecific uptake. The GFP-tagged PCFT was used in this study for easier inspection of its expression by visual observation of GFP-derived fluorescence.
Materials and Methods

Chemicals
Data analysis: In Caco-2 cells, the uptake rate (v) was estimated for the initial 10-min uptake period, in which uptake was almost in proportion to time. The v was assumed to consist of a carrier-mediated component represented by a single MichaelisMenten equation and a nonsaturable component as follows:
The apparent parameters of maximum transport rate (V max ), the Michaelis constant (K m ) and the clearance of nonsaturable transport (CL ns ) were estimated by fitting this equation to the experimental profile of v versus s, using a nonlinear least-squares regression analysis program, WinNonlin (Pharsight, Mountain View, CA), and v ¹2 as the weight. A set of parameters was estimated for a profile, in which v was estimated as the mean of duplicate determinations at each s, and then the mean of each parameter was estimated with its SE using three sets of parameters.
Based on the assumption of noncompetitive inhibition, V max in the presence of an inhibitor (V max,i ) can be related to that in its absence (V max,0 ), using the inhibitor concentration (i) and the inhibition constant (K i ), as follows:
Based on this equation, the K i was estimated using the mean values of V max,i and V max,0 , and the experimentally designated value of i.
In PCFT-transfected MDCKII cells, the initial rate of specific uptake by PCFT was estimated for a shorter period of 2 min and by subtracting the uptake rate in mock cells from the total rate of uptake in the PCFT-transfected cells. It was designated to be v c as the one equivalent to the carrier-mediated component of v and assumed to consist of the single Michaelis-Menten term. The v c was kinetically analyzed as described above for the analysis of v in Caco-2 cells.
Experimental data are presented as means « SE. Statistical analysis was performed by using Student's t-test or, when multiple comparisons were needed, ANOVA followed by Dunnett's test, with p < 0.05 considered significant.
Results
Effect of myricetin on the uptake of folate in Caco-2 cells: The initial set of experiments was conducted to assess the effect of myricetin on the uptake of folate into the Caco-2 cell as an intestinal epithelial cell model, in which PCFT has been suggested to be responsible for folate uptake, under an acidic condition of pH 5.5, where this H + -dependent transporter can operate efficiently. 9) As shown in Figure 1 , the uptake rate of folate was reduced extensively by myricetin (100 µM) in the entire range of folate concentration up to 20 µM. Kinetic analysis indicated that it was solely attributable to a significant reduction in V max of about 60% from 3.23 pmol/min/mg protein in the absence of myricetin to 1.23 pmol/min/mg protein in its presence, whereas neither K m (0.407 µM in the absence of myricetin and 0.453 µM in its presence) nor CL ns (0.221 µL/min/mg protein in the absence of myricetin and 0.208 µL/min/mg protein in its presence) was altered ( Table 1) . Thus, as can be confirmed by the Eadie-Hofstee plots of the carrier-mediated component of the uptake rate, myricetin was suggested to inhibit the transport of folate by PCFT as its carrier noncompetitively, acting on a binding site different from the substrate recognition site of the substrate-bound form of the transporter as well as its substrate-free form. Based on the assumption of noncompetitive inhibition, K i was estimated to be 61 µM.
Effect of myricetin on PCFT stably expressed in MDCKII cells: In the subsequent set of experiments using MDCKII cells stably expressing PCFT, the specific uptake of folate by PCFT was found to be extensively inhibited by myricetin (100 µM) also in a noncompetitive manner, as shown in Figure 2 and Table 1 . The reduction in V max by about 40% from 36.67 pmol/min/mg protein in the absence of myricetin to 20.82 pmol/min/mg protein in its presence was significant and comparable to that observed in Caco-2 cells, whereas K m was not altered, being 1.246 µM in the absence of myricetin and 1.369 µM in its presence. Based on the assumption of noncompetitive inhibition, K i was estimated to be 130 µM. Thus, we could confirm the noncompetitive type of inhibitory action of myricetin on the cloned PCFT, although the K m and K i were similarly shifted to some extent to be smaller in Caco-2 cells.
Effect of various flavonoids on PCFT stably expressed in MDCKII cells: As an attempt to extend the study, we examined the effect of some other flavonoids on the cloned PCFT. To assess the type of inhibition briefly, we examined the effect of each flavonoid on folate uptake in MDCKII cells stably expressing PCFT at a high folate concentration of 5 µM, where the maximum uptake rate is almost achieved and, hence, v c can be assumed to be sensitive to an alteration in V max , as well as at a low folate concentration of 5 nM in the linear phase of v c versus s profile, where v c is almost proportional to s with the coefficient of V max /K m and, hence, it is sensitive to an alteration in V max /K m (Fig. 2) . As shown in Table 2 , we first confirmed the noncompetitive type of Fig. 1 . Effect of myricetin on the kinetics of folate uptake in Caco-2 cells The uptake rate of folate was evaluated for the initial 10-min period at pH 5.5 and 37°C in the absence of myricetin ( ) or in its presence at 100 µM ( ). Eadie-Hofstee plots are shown in the right panel for the carrier-mediated component of uptake rate (v c ). Data are presented as means « SE (n = 3). Lines represent simulation profiles based on the kinetic parameters summarized in Table 1 . Data are presented as means « SE (n = 3). *p < 0.05 compared with control. NA, not applicable.
Fig. 2. Effect of myricetin on the kinetics of folate uptake by PCFT stably expressed in MDCKII cells
The specific uptake rate of folate was evaluated for the initial 2-min period at pH 5.5 and 37°C in the absence of myricetin ( ) or in its presence at 100 µM ( ), and is in the right panel shown in the Eadie-Hofstee format. Data are presented as means « SE (n = 3). Lines represent simulation profiles based on the kinetic parameters summarized in Table 1 .
inhibitory action of myricetin on PCFT by the observation that myricetin could inhibit the specific uptake of folate by PCFT at the high folate concentration to an extent comparable to that at the low folate concentration consistently at its two different concentrations. Among flavonoids tested in this section, EGCG, which is typically contained in teas and has also been reported to inhibit folate uptake in Caco-2 cells, 4, 5) was also suggested to be a noncompetitive inhibitor, since this flavonoid inhibited the specific uptake of folate by PCFT to almost the same extents at both the high and low folate concentrations. This flavonoid was, moreover, found to be as potent as myricetin in the inhibition. Naringenin and naringin were also included in the tested flavonoids since they have been of interest for their inhibitory effects on OATPs as drug transporters and may possibly inhibit some other transporters. 15, 16) Naringenin was indeed found to inhibit specific folate uptake, but, interestingly, to different extents depending on folate concentration. The inhibitory effect by this flavonoid was only modest and weaker than that by myricetin at the low concentration, whereas it was more extensive and comparable with that by myricetin at the high concentration. This inhibitory profile may indicate that K m is reduced by this flavonoid to a similar extent as V max and, hence, it may be an uncompetitive inhibitor, which acts on a binding site different from the substrate recognition site of the substrate-bound form, but not of the substrate-free from, of the transporter. Naringin was, however, found not to inhibit the specific uptake of folate at the either concentration.
A series of experiments was similarly conducted, using methotrexate as another substrate, to further confirm the inhibitory actions of those flavonoids. The results were mostly in agreement with those for folate, as shown in Table 2 . First, myricetin and EGCG were found to inhibit specific methotrexate uptake similarly at both the low and high methotrexate concentrations, indicating that they are similarly potent noncompetitive inhibitors. Secondly, inhibition by naringenin was only modest at the low concentration and more extensive at the high concentration, indicating the uncompetitive type of inhibitory mechanism. Lastly, inhibition by naringin was negligible at the low concentration and only modest at the high concentration. The observation of modest but significant inhibition only at the high concentration by this aglycone of naringenin may indicate that it also acts as a weak uncompetitive inhibitor of PCFT. However, taking into consideration that its inhibitory effect was not observed at either concentration on folate uptake, it is likely that naringin is not very effective as an inhibitor at the tested concentration of 100 µM or at least it is far less potent as an inhibitor than naringenin.
Discussion
The present study has demonstrated that myricetin indeed inhibits PCFT, consistent with the earlier indication in a study using the Caco-2 cell as an intestinal epithelial cell model expressing PCFT. 4) Moreover, kinetic analysis of the inhibition revealed that it is of the noncompetitive type. A similar noncompetitive type of inhibition was also suggested for EGCG as another inhibitory flavonoid. It was suggested on the other hand that naringenin might be an uncompetitive inhibitor of PCFT. Naringin may also be an uncompetitive inhibitor, although less potent. It may not be surprising to find that those flavonoids are not competitive to folate because they are not structurally related to the substrate, but it would be of interest to further examine the factors that determine those inhibitors to be noncompetitive or uncompetitive.
Myricetin is reportedly present in red grape wines at a concentration as high as about 60 µM, 17) which is comparable with the K i of myricetin for PCFT in Caco-2 cells and somewhat lower than that for cloned PCFT. It is generally difficult to estimate the concentration of a solute in the intestinal lumen after its ingestion because of dilution with luminal contents and concentration by water absorption. Still, the concentration in the ingested solution could be a reference to discuss possible events caused by the solute. Therefore, based on these considerations, inhibition of PCFT-mediated folate transport would not be very pronounced in practical situations, though it might occur. However, it is notable that, as a feature of the noncompetitive type of inhibition, inhibition is supposed to be maintained even at high substrate concentrations where it could be negligible in the case of competitive inhibition. Although information is not available about the luminal concentration of dietarily ingested folate, the concentration of folate would be about 5 µM initially when a typical supplemental dose of 400 µg is taken with 200 mL of water or a beverage. It is around concentrations where the maximum uptake rate is almost achieved. The concentration of methotrexate would be even higher, being about 20 µM, when a typical dose of 2 mg for rheumatoid arthritis is taken with 200 mL of water or a beverage. The maximum uptake rate of this drug, of which the affinity for PCFT is comparable with that of folate, 13) is likely to be achieved at this concentration. Thus, such high concentrations of folate and methotrexate would possibly be achieved in the intestinal lumen and, hence, care may need to be taken in the ingestion of myricetin.
It has recently been reported that naringin is a potent inhibitor of OATP2B1 with an IC 50 of 4.63 µM. 16) However, the effect of The specific uptake rates of folate and methotrexate were evaluated for the initial 2-min period at pH 5.5 and 37°C in the presence of a test flavonoid or in its absence. Control values were 132 and 268 fmol/min/mg protein, respectively, for folate and methotrexate at 5 nM, and 31.1 and 82.0 pmol/min/mg protein, respectively, at 5 µM. EGCG, epigallocatechin-3-gallate. Data are presented as means « SE (n = 3). *p < 0.05 compared with control; † p < 0.05 compared with the value for 5 nM substrate. ND, not determined. naringin on PCFT was barely observed at its concentration of 100 µM, suggesting that it is not effective as an inhibitor to PCFT or at least very weak in inhibitory potency with an IC 50 much greater than 100 µM. It is also notable that naringenin is reportedly less potent as an OATP2B1 inhibitor, with an IC 50 of 49.2 µM, than naringin. 16) However, naringenin was found to be more potent as a PCFT inhibitor than naringin. Furthermore, their inhibitory effects on OATP2B1 were observed at a low substrate (estrone-3-sulfate) concentration in the linear phase of transport in the study. Therefore, it is likely that their inhibitory action on OATP2B1 is of the competitive or noncompetitive type, being different from the uncompetitive type suggested for their action on PCFT. Thus, overall, these flavonoids were suggested to act on PCFT rather modestly and in a manner quite different from their action on OATP2B1.
In conclusion, myricetin was found to inhibit PCFT. Furthermore, its inhibitory action was found to be of the noncompetitive type, in which inhibition is supposed to be maintained even at high substrate concentrations, and similar inhibitory effect was also suggested for EGCG as another inhibitory flavonoid. Care may need to be taken, therefore, in the ingestion of myricetin and some flavonoids to maintain the absorption of folate and antifolate drugs.
